Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), T. Maher (Los Angeles, California, United States of America), K. Ichikado (Kumamoto, Japan), J. Oldham (Sacramento, California, United States of America), C. Valenzuela (Madrid, Spain), H. Mueller (Biberach, Germany), K. Rohr (Ingelheim am Rhein, Germany), K. Flaherty (Ann Arbor, Michigan, United States of America). Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial. 2974

Member's Comments

No comment yet.

Related content which might interest you: Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry Source: Eur Respir J, 55 (4) 1901855; 10.1183/13993003.01855-2019 Year: 2020 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Elevated leukocyte count predicts survival in patients with idiopathic pulmonary fibrosis: analysis from the Swedish and Japanese cohorts Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Clinical significance of blood neutrophil differential count in patients with COPD Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Association between blood eosinophil count and risk of exacerbations in patients with COPD Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives Year: 2019 Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of COPD. Source: International Congress 2017 – Highlights on clinical problems in COPD Year: 2017 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 ERS guidelines on treatment of sarcoidosis Source: ERS webinar 2021: ERS guidelines on treatment of sarcoidosis Year: 2021